| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/01/2007 | CA2192813C Methods of inducing gene expression by ionizing radiation |
| 05/01/2007 | CA2191440C Treatment and prevention of helicobacter infection |
| 05/01/2007 | CA2185394C Biotinderivate |
| 05/01/2007 | CA2121497C T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| 05/01/2007 | CA2120303C Cyclic adhesion inhibitors |
| 05/01/2007 | CA2081704C Biosynthetic process for the preparation of lantibiotics |
| 04/30/2007 | CA2564316A1 Slc1a1 marker for anxiety disorder |
| 04/30/2007 | CA2528222A1 Slc1a1 marker for anxiety disorder |
| 04/26/2007 | WO2007048120A2 Treatment of proliferative disorders with polycationic agents |
| 04/26/2007 | WO2007048047A1 Glycolated and glycosylated poultry derived therapeutic proteins |
| 04/26/2007 | WO2007047997A2 Methods for reducing the mitogenicity of lectin compositions |
| 04/26/2007 | WO2007047995A2 Modified proteases that inhibit complement activation |
| 04/26/2007 | WO2007047922A2 Polymer-drug conjugates |
| 04/26/2007 | WO2007047882A2 Combination of cxcr4 antagonist and morphogen to increase angiogenesis |
| 04/26/2007 | WO2007047834A2 Oral peptide conjugates for metabolic diseases |
| 04/26/2007 | WO2007047811A2 Improved reproductive management |
| 04/26/2007 | WO2007047764A2 Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| 04/26/2007 | WO2007047763A2 Bcr-abl vaccines and methods of use thereof |
| 04/26/2007 | WO2007047754A2 Mtor pathway theranostic |
| 04/26/2007 | WO2007047738A1 Il-17c antagonists and methods of using the same |
| 04/26/2007 | WO2007047608A2 Fibrin targeted therapeutics |
| 04/26/2007 | WO2007047577A2 Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders |
| 04/26/2007 | WO2007047551A2 Methods and compositions for derepression of iap-inhibited caspase |
| 04/26/2007 | WO2007047504A2 Natriuretic peptide modified transferrin fusion proteins |
| 04/26/2007 | WO2007047489A2 Compositions and methods for use in cancer therapy |
| 04/26/2007 | WO2007047430A2 Method of treating acute failure with thrombomodulin variant |
| 04/26/2007 | WO2007047334A1 Prevention and treatment of drug-associated ocular side effects with a cyclosporin |
| 04/26/2007 | WO2007047244A2 Functionalized amino acids and absorbable polymers therefrom |
| 04/26/2007 | WO2007047242A2 Ophthalmic surgical irrigating solutions containing hyaluronidase |
| 04/26/2007 | WO2007047194A2 Methods for treating mitf-related disorders |
| 04/26/2007 | WO2007046834A2 Glp-1 agonists, compositions, methods and uses |
| 04/26/2007 | WO2007046729A1 Method of acting upon organism by targeted delivery of biologicaly active substances into m itochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose |
| 04/26/2007 | WO2007046540A1 Therapeutic agent for dentine-dental pulp complex regeneration |
| 04/26/2007 | WO2007046127A1 Platelet aggregation inhibitor and health food effective in inhibiting platelet aggregation |
| 04/26/2007 | WO2007046087A2 Pharmaceutical compositions and diagnostic methods for inflammatory skin disesaes, disorders or conditions |
| 04/26/2007 | WO2007045982A2 Use of collagen in combination with oxygen- and ozonereleasing perfluorocarbons for the preparation of a medicament for the treatment of skin lesions |
| 04/26/2007 | WO2007045955A2 Osteogenic device for inducing bone formation in clinical contexts |
| 04/26/2007 | WO2007045911A1 Integral membrane protein |
| 04/26/2007 | WO2007045906A1 Rfamide-related peptide precursor proteins and rfamide peptides |
| 04/26/2007 | WO2007045873A2 Medical uses and therapies based upon the action of azurocidin on igfbp-1 |
| 04/26/2007 | WO2007045450A2 Use of fructanases in feed of hoofed animals to treat and prevent laminitis |
| 04/26/2007 | WO2007045389A2 Method for discovering inhibitors of the epstein-barr virus-induced gene 3 (ebi3) and derivatives thereof for the treatment of metastasizing tumors and allergic asthma |
| 04/26/2007 | WO2007045252A2 An edible composition |
| 04/26/2007 | WO2007045251A2 A composition comprising a coupled enzyme system |
| 04/26/2007 | WO2007045184A1 The peptides essence receptor antagonist which 2-site containing proline or crico-amino acid |
| 04/26/2007 | WO2007045046A1 Treatment of hypersensitivity |
| 04/26/2007 | WO2007028133A3 Treatment and prevention of vascular dementia |
| 04/26/2007 | WO2007024946A3 Methods for the treatment of anxiety and for identification of anxiolytic agents |
| 04/26/2007 | WO2007017067A3 Modulators of the melted protein and uses thereof |
| 04/26/2007 | WO2007012944A3 Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus |
| 04/26/2007 | WO2007005733A3 Novel peptides promoting neurite outgrowth |
| 04/26/2007 | WO2006138608A3 Pharmaceutical compositions and use thereof |
| 04/26/2007 | WO2006132665A3 Biocides |
| 04/26/2007 | WO2006131874A3 Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
| 04/26/2007 | WO2006129191A3 A method for optimized production of a recombinant form of tissue plasminogen activator |
| 04/26/2007 | WO2006125139A3 Therapeutic uses of kallikreins |
| 04/26/2007 | WO2006122139A3 Use of tfpi to treat severe bacterial infections |
| 04/26/2007 | WO2006110591A3 POP2 NFkB-INHIBITING POLYPEPTIDES, NUCLEIC ACIDS AND METHODS OF USE |
| 04/26/2007 | WO2006097327A3 Soluble btnl2 protein useful to inhibit inflammatory disorders |
| 04/26/2007 | WO2006083706A3 Method to identify polypeptide toll-like receptor (tlr) ligands |
| 04/26/2007 | WO2006081546A3 Inhibitor nucleic acids |
| 04/26/2007 | WO2006066234A3 Compositions and methods for reducing lung volume |
| 04/26/2007 | WO2006042242A3 Amylin family polypeptide- 6 (afp- 6) analogs and methods of making and using them |
| 04/26/2007 | WO2006036700A3 Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
| 04/26/2007 | WO2006012541A8 Compositions and methods for treating excessive bleeding |
| 04/26/2007 | WO2006011151A8 Vaccine comprising recombinant ct or lt toxin |
| 04/26/2007 | WO2005091777A3 Methods and materials relating to insulin growth factor-like (igfl) polypeptides and polynucleotides |
| 04/26/2007 | WO2005041859A3 Conjugates and compositions for cellular delivery. |
| 04/26/2007 | WO2005005612A3 Tag-1 and tag-2 proteins and uses thereof |
| 04/26/2007 | US20070093645 Peptide vectors |
| 04/26/2007 | US20070093445 RNA interference mediating small RNA molecules |
| 04/26/2007 | US20070093441 useful to efficiently induce self-specific immune responses; comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin |
| 04/26/2007 | US20070093440 Gene expression inhibition by targeting a component of a human Notch signalling pathway other than presenilin1 or presenilin2 with a RNA interference ( RNAi ) agent; modulating immune responses; targeting T-cells, B-cells and antigen presenting cells; antiallergens; immunotherapy |
| 04/26/2007 | US20070093437 Study and interfererance, diagnosis and treatment of polyglutamine using short interfering nucleic acid for treatment of dementia or siezures or muscular dystrophy |
| 04/26/2007 | US20070093436 Drop1, a novel marker for carcinogenesis |
| 04/26/2007 | US20070093435 Modulation of cell phenotype by inhibitory rna |
| 04/26/2007 | US20070093434 Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
| 04/26/2007 | US20070093431 N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide as renin inhibitor and an antidiabetic agent (insulin secretion enhancer or sensitizer); synergistic effect on related isolated systolic hypertension and vascular compliance |
| 04/26/2007 | US20070093430 Interferons; polyoxyethylene glycol |
| 04/26/2007 | US20070093429 Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents |
| 04/26/2007 | US20070093428 IAP BIR domain binding compounds |
| 04/26/2007 | US20070093427 Membrane-permeable NFAT inhibitory peptide |
| 04/26/2007 | US20070093426 Peptides from amino acid residues of human histone H2A: thermal burns, chemical burns, autoimmune diseases, arthritis, multiple sclerosis |
| 04/26/2007 | US20070093425 Improved safety and stability and excellent percutaneous permeability; 6-(succinyl-glycyl-histidyl-lysine)ascorbic acid; cosmetics; for topical application to the skin |
| 04/26/2007 | US20070093424 drugs that bind and neutralize bacterial lipopolysaccharides, used for prevention or treatment of endotoxic shock or sepsis |
| 04/26/2007 | US20070093423 Process for production of Bivalirudin |
| 04/26/2007 | US20070093422 Drug comprising synthetic peptide analogs for the treatment of cancer |
| 04/26/2007 | US20070093421 Bio-security system |
| 04/26/2007 | US20070093420 Therapy procedure for drug delivery for trigeminal pain |
| 04/26/2007 | US20070093419 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent |
| 04/26/2007 | US20070093418 Methods of treatment using specific binding agents of human angiopoietin-2 |
| 04/26/2007 | US20070093417 Novel GLP-1 analogues linked to albumin-like agents |
| 04/26/2007 | US20070093416 Human beta-defensin secretion promoter |
| 04/26/2007 | US20070093415 polypeptide comprising amino acid sequences that interact with amyloid plaques containing amyloid beta (A beta ) peptide, useful as carrier molecules to deliver drugs and diagnostic reagents to amyloid plaques |
| 04/26/2007 | US20070093414 Hepatitis C virus inhibitors |
| 04/26/2007 | US20070093413 Histone deacetylases, and uses related thereto |
| 04/26/2007 | US20070093412 Pharmaceutical composition comprising cyclic somatostatin analogues |
| 04/26/2007 | US20070093411 Diabetic inhalant formulation including surfactant and optionally preservative, isotonicizing agent, buffer and/or excipient |
| 04/26/2007 | US20070093410 Selective inhibition of proteasomes of tuberculosis and other bacteria |
| 04/26/2007 | US20070092948 DNA segment encoding the enzyme inhibitor for therapy of thrombosis, blood disorders; biodrugs; genetic vaccines; monoclonal antibodies; host cells |